In today's rapidly evolving technological landscape and the growing intersection of industries, the seemingly unrelated fields of biopharmaceuticals, stainless steel, and cranes actually hold significant potential for innovation and collaboration.
Fortis Healthcare, a key player in healthcare services, has reported a 40.4% increase in net profit to Rs. 174 crore in the first quarter ending June 2024, a comparison to Rs. 124 crore during the corresponding period of the previous financial...
The government no longer requires clinical trials for new drugs that offer major improvements over current standard care and already have regulatory approval in the US, UK, Japan, Australia, Canada or the European Union. The CDSCO stated that...
Praxis Global Alliance states that the Indian diagnostics sector, currently worth approximately $13 billion in FY23, is expected to experience a growth rate of about 14% per year over the next five years. The Indian healthcare industry is on the...
Daiichi Sankyo and Merck, also known as MSD internationally, have broadened their current global collaboration agreement to include Merck's MK-6070, an experimental T-cell engager aimed at delta-like ligand 3 (DLL3), alongside three...
Ocugen, Inc., a biotech company specializing in innovative gene and cell therapies and vaccines, disclosed that FDA has granted approval to initiate its expanded access program for using OCU400 on adult patients, 18 years and above, with retinitis...
Mallinckrodt plc, a worldwide specialty pharmaceutical company, and CVC Capital Partners, a top investment firm, have confirmed a deal where CVC Capital Partners Fund IX will buy the company's Therakos business for $925 million with standard...
Tecelra (afamitresgene autoleucel), a gene therapy, has been approved by the FDA for treating adults with unresectable or metastatic synovial sarcoma. Patients must have received prior chemotherapy, be positive for specific HLA antigens, and have...
European Medicines Agency (EMA) initiated a pilot program for expert panels to assist in the creation and evaluation of rare medical devices in the EU. The pilot program provides free guidance from medical device expert panels to specific...
Chugai Pharmaceutical Co., Ltd. reported the announcement of Chugai Pharma Taiwan Ltd. Chugai's subsidiary CPT received a license from TFDA to import Alecensa for ALK-positive NSCLC patients post-tumour resection. CPT manages the development...